Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26
Rhea-AI Summary
MDxHealth (NASDAQ: MDXH) will release fourth quarter and full year 2025 financial results after market close on February 26, 2026. A conference call and live webcast with Q&A is scheduled for February 26, 2026 at 4:30pm ET / 22:30 CET.
Investors can join via listed dial‑in numbers or the provided webcast link and should connect 15 minutes early; a replay will be available on the company website.
Positive
- None.
Negative
- None.
News Market Reaction – MDXH
In the Feb 13 session, MDXH declined 0.58%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 12 | Q3 2025 earnings | Positive | -7.4% | Reported Q3 2025 growth and Exosome Diagnostics acquisition but shares fell sharply. |
| Feb 26 | FY 2024 earnings | Positive | +1.6% | Strong Q4 and 2024 growth with improved losses and maintained 2025 guidance. |
| Nov 06 | Q3 2024 earnings | Positive | +0.5% | Q3 2024 revenue growth and guidance raise alongside equity offering and higher losses. |
| Mar 06 | FY 2023 earnings | Neutral | -17.4% | Fourth quarter and full-year 2023 financial results release with a negative price reaction. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings events have seen mixed reactions, with an average move of -5.68% and at least one sharp post-earnings selloff.
Over the last two years, MDXH has regularly reported strong revenue growth in its earnings releases, alongside ongoing net losses and balance-sheet actions. Q3 2025 results showed higher revenue and margins but a net loss and a negative -7.42% move. Earlier, Q4 and full-year 2024 results highlighted 28% revenue growth and improving EBITDA, with a modestly positive share reaction. The current announcement simply schedules the Q4 and 2025 release, continuing this established reporting cadence.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26
Company to Host Conference Call with Live Q&A, February 26, 2026, at 4:30pm ET / 22:30 CET
IRVINE, California – February 12, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the fourth quarter and full year ended December 31, 2025, after market close on Thursday, February 26, 2026.
| Title: | Mdxhealth Presents Fourth Quarter and Full Year 2025 Financial Results and Corporate Update Conference Call and Webcast |
| Date: | February 26, 2026 |
| Time: | 4:30pm ET/ 22:30 CET |
| Conference Call Dial-in Details: | United States: 1-844-825-9789 Int’l: 1-412-317-5180 Belgium: 0800 38 961 United Kingdom: 0800 279 9489 |
| Conference ID: | 10206764 |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1753070&tp_key=27bce7d4de |
The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live call and will be accessible on the Company’s website.
About Mdxhealth
Mdxhealth is a leading precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests are based on proprietary genomic, epigenetic (methylation), exosomal and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases. The Company’s U.S. headquarters and laboratory operations are in Irvine, California, with additional laboratory operations in Waltham, Massachusetts and Plano, Texas. European headquarters are in Herstal, Belgium. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
For more information:
info@mdxhealth.com
LifeSci Advisors (IR & PR)
John Fraunces
Managing Director
Tel: +1 917 355 2395
Jfraunces@lifesciadvisors.com
Attachment
